BioTuesdays

Category - Markets

Arcus Biosciences
Markets

BTIG starts Arcus Biosciences at buy; PT $20

BTIG initiated coverage of Arcus Biosciences (NYSE:RCUS) with a “buy” rating and $20 price target. The stock closed at $11.67 on March 15. Arcus is focused on driving antitumor immune responses beyond the level...

March 18, 2019
Fluidigm
Markets

BTIG starts Fluidigm at buy; PT $15

BTIG launched coverage of Fluidigm (NASDAQ:FLDM) with a “buy” rating and price target of $15. The stock closed at $12.79 on March 13. Analyst Sung Ji Nam writes that the long-term growth or market potential for the...

March 14, 2019
Vapotherm Logo
Markets

Canaccord ups Vapotherm PT to $27 from $22

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $27 from $22 after the company’s fourth quarter results beat expectations. The stock closed at $19.85 on March 12. The company, which develops non...

March 13, 2019
Senseonics
Markets

BTIG ups Senseonics PT to $4 from $3

BTIG raised its price target for Senseonics (NYSE American:SENS) to $4 from $3, saying the company’s new Patient Access Bridge program makes strategic sense, even though it caused Senseonics to lower its 2019 guidance...

March 13, 2019
Markets

SVB Leerink starts TCR2 Therapeutics at OP; PT $27

SVB Leerink launched coverage of TCR2 Therapeutics (NASDAQ:TCRR) with an “outperform” rating and $27 price target. The stock closed at $15.64 on March 8. TCR2 is a clinical-stage cell therapy company developing a...

March 11, 2019
Avedro
Markets

SVB Leerink starts Avedro at OP; PT $20

SVB Leerink initiated coverage of Avedro (NASDAQ:AVDR) with an “outperform” rating and $20 price target. The stock closed at $11.70 on March 8. Analyst Danielle Antalffy writes that the company’s key growth driver is...

March 11, 2019
Anchiano Therapeutics
Markets

Ladenburg starts Anchiano Therapeutics at buy; PT $20

Ladenburg Thalmann initiated coverage of Anchiano Therapeutics (NASDAQ:ANCN) with a “buy” rating and $20 price target. The stock closed at $7.72 on March 8. Anchiano is focused on applying its gene therapy technology as...

March 11, 2019